2 min read
The primary South Korea’s pharmaceutical Regulatory authority for medicinal products is the Ministry of Food and Drug Safety (MFDS). MFDS is responsible for overseeing the safety, efficacy, and quality of pharmaceutical products, ensuring compliance with national regulations and international standards. MFDS is a member of the International Council for Harmonisation (ICH) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), reflecting South Korea’s alignment with global regulatory standards.
For companies planning market entry, understanding the South Korea drug approval process and evolving Korea pharmaceutical regulations is essential to ensure compliant product development, timely submissions, and successful commercialization strategies.
Its structure, roles, and functions are outlined below.
Structure and Organization
The MFDS consists of:
- The main Headquarters
- The National Institute of Food and Drug Safety Evaluation (NIFDS), the research and evaluation arm of the MFDS
- Six Regional Offices of Food and Drug Safety
These entities coordinate to manage processes and enforcement nationwide. The MFDS South Korea became independent from the Ministry of Health and Welfare in March 2013.
Key Regulatory Responsibilities and Functions
| Function | Description |
|---|---|
| Pharmaceutical Registration | Oversee the application, review, and MFDS drug approval process for medicinal products. |
| Approval and Licensing | Issues marketing authorization, permits, approval variations, and patent linkage. |
| Surveillance and Inspection | Conducts regular surveillance, written and onsite inspections of manufacturers/importers. |
| Post-Market Surveillance | Manages the post-marketing safety, quality controls, and product recalls, and pharmacovigilance activities including adverse event reporting and risk management plans (RMPs). |
| GMP & Quality Control | Inspects Good Manufacturing Practice (GMP) compliance and sets quality requirements. |
| International Cooperation | Engages with agencies like the EMA for joint reviews and Regulatory harmonization. |
| Regulatory Innovation | Implements new policies to support innovative products, biosimilars, and Regulatory science. MFDS has also introduced expedited review pathways such as GIFT (Global Innovative Product on Fast Track) for innovative therapies and orphan drugs. |
| Complaints & Consultation | Provides guidance and complaint mechanisms for industry stakeholders and facilitates export. |
Legislative and Regulatory Basis
The MFDS enforces the Pharmaceutical Affairs Act along with various enforcement decrees and Regulatory guidelines.
As South Korea’s pharmaceutical Regulatory authority, the agency sets and updates standards for product approval, labeling, manufacturing, and pharmacovigilance. Regulatory procedures include written evaluations, onsite inspections, and continuous improvements aligned with domestic and international Regulatory trends.
The agency continuously updates Korea pharmaceutical regulations to align with global best practices, helping strengthen South Korea’s position as a major pharmaceutical and biotechnology market in Asia.
Supporting Activities
- Regular publication of guidelines and annual reports (e.g., National Lot Release, manufacturing changes).
- Transparent Regulatory notices and public engagement via the agency’s official website (and the Nedrug/DrugSafety online portal).
- A hotline and consultation program for innovative product development and global market entry.
Post-Market Activities
- Ongoing surveillance as per the Basic Plan for Manufacturing and Distribution Management.
- Enforcement through regular and event-driven inspections, as well as Re-examination/Re-evaluation systems.
- Engagement with stakeholders (pharmaceutical associations, hospitals, import/export councils) for recall, change notification, and safety management.
- Post-marketing re-examination and re-evaluation activities to ensure continued product safety and efficacy throughout the product lifecycle.
Conclusion
As South Korea’s pharmaceutical Regulatory authority, the MFDS plays a critical role in ensuring the safety, quality, and efficacy of medicinal products throughout their lifecycle.
Understanding MFDS drug approval requirements, the South Korea drug approval process, and ongoing compliance obligations under evolving Korea pharmaceutical regulations is critical for successful market entry and sustained operations in South Korea.
Freyr supports organizations with end-to-end Regulatory assistance, including product registration, lifecycle management, labeling support, GMP compliance, and post-approval Regulatory services in South Korea. To learn more about Freyr’s Regulatory support services, fill out the contact form or write to us at sales@freyrsolutions.com.
